Three quarters of patients, both adults and children, with a variety of advanced cancers occurring in different sites of the body responded to larotrectinib, a novel therapy that targets a specific genetic mutation. Results of this multisite phase 12 trial have been published in the New England Journal of Medicine on February 22, 2018. Unlike most cancer therapies, this oral treatment is based on the genetic traits of the tumor and not the organ where the cancer originated.

Source: Click here

Share this article

Facebook Comments